Strategy resumed Bitcoin buying after a one-week pause, purchasing 811 BTC for $65.5 million at an average price of $80,846 per coin between October 26 and November 1. The company funded these purchases by selling shares of its stock, raising $164 million, and also repurchased $208.2 million of its preferred stock using USD Cash. Strategy now holds 849,327 BTC acquired for about $64.08 billion at an average of $75,451 per coin, with USD Cash reduced to $132.7 million. The company also started daily dividends on its preferred stocks and faces potential removal from MSCI indexes due to its asset concentration.
The story on Strategy's Bitcoin buying activity is presented here with Pluang's cryptocurrency market context as of Nov 02, 2026 19:42 WIB: Among 50 major cryptocurrencies tradable on Pluang, only 7 rose while 42 fell. Notable movers include EOS (EOS.IO) up 8.13% to Rp12,649 with a typical hold time of 87 days, BAT (Basic Attention Token) down 5.58% to Rp2,394 with 73% sell order activity, and CRV (Curve DAO Token) down 4.46% to Rp4,969 with 57% sell order activity and a typical hold time of 62 days.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
